Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TGF-β receptor-specific NanoBRET target engagement in living cells for high-throughput kinase inhibitor screens

  • Wits, Marius
  • Haarmans, Nicole
  • Sánchez-Duffhues, Gonzalo
  • Goumans, Marie-José
Targeting transforming growth factor-β (TGF-β) receptors is a promising pharmacological approach to normalize aberrant signaling in genetic and non-genetic TGF-β associated diseases including fibrosis, cancer, cardiovascular and musculoskeletal disorders. To identify novel TGF-β receptor kinase inhibitors, methods like in vitro kinase assays, western blot or transcriptional reporter assays are often used for screening purposes. While these methods may have certain advantages, the lack of integration of key features such as receptor specificity, high-throughput capability, and cellular context resemblance remains a major disadvantage. This deficiency could ultimately hinder the translation of study outcomes into later (clinical) stages of drug development. In this study, we introduce an adjusted and optimized live cell NanoBRET Target Engagement (TE)-based method to identify TGF-β receptor specific kinase inhibitors. This comprehensive toolkit contains various TGF-β type I and type II receptors, with corresponding nanoBRET tracers, and disease-related cell lines, including novel non-commercially available materials. The nanoBRET capacity and kinase inhibitory window can be significantly enhanced for functional measurements when stable expression cell lines and substantially low tracer concentrations are used. In addition, this system can be tailored to study TGF-β associated genetic disorders and possibly be used to screen for disease-specific therapeutics. Therefore, the use of this optimized, live cell, antibody-independent nanoBRET Target Engagement assay is highly encouraged for future high-throughput compound screens targeting TGF-β/BMP receptors., We acknowledge the support from Promega R&D. Galapagos NV provided funding for the conduct of the study and the compounds A-D. Some figures were made using Biorender.com. This research was further supported by grants Ramón y Cajal RYC2021-030866-I, PID2022-141212OA-I00 and CNS2023-145432 from the Spanish Ministry of Science and Innovation (to GSD). GSD is also sponsored by La Marató de TV3 (202038-30), the BHF-DZHK-DHF, 2022/23 award PROMETHEUS (02-001-2022-0123), the Foundation Eugenio Rodriguez Pascual (FERP-2023-058) and the Foundation “Por dos pulgares de nada”. MW and MJG are sponsored by the Netherlands Cardiovascular Research Initiative (the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences), PHAEDRA-IMPACT (DCVA) and DOLPHIN-GENESIS (CVON). Finally, we thank the Scientific Research Network by the Research Foundation–Flanders (WOG W0014200N) and An Zwijsen., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A cost-effective vessel-on-a-chip for high shear stress applications in vascular biology

  • Becher, Clarissa
  • Frauenlob, Martin
  • Selinger, Florian
  • Ertl, Peter
  • Goumans, Marie-José
  • Sánchez-Duffhues, Gonzalo
The data supporting the findings of this study can be obtained from the corresponding authors upon reasonable request., The vascular endothelium is constantly subjected to hemodynamic forces, including tangential shear stress, which are crucial for maintaining vascular homeostasis. Pathological shear stress levels, such as those observed in pulmonary arterial hypertension (PAH) or atherosclerosis, disrupt this balance, driving vascular remodeling and endothelial dysfunction. Current microfluidic platforms for studying these conditions are limited by high costs, excessive reagent requirements, and non-physiological channel geometries. Here we introduce a novel microfluidic chip system, a Nylon Vessel-on-a-Chip (NVoC) which represents a cost-effective and straightforward fabrication platform that eliminates the need for specialized equipment and enables a physiologically relevant round channel geometry. The NVoC was fabricated using Polydimethylsiloxane (PDMS) and nylon threads, with surface activation achieved through polydopamine and collagen-I coating, enabling robust endothelial cell (EC) attachment and long-term culture. Immortalized endothelial colony-forming cells (iECFCs) and human umbilical vein EC (HUVECs) were used to optimize and validate the platform, demonstrating its compatibility with high shear stress conditions (up to 90 dyne/cm2) and various molecular biology techniques, including RT-qPCR, Western blotting, and immunofluorescent staining. With fabrication costs six times lower than commercial alternatives and overall experimental costs reduced threefold, the NVoC offers the ability to expose endothelial cells to physiological and pathological shear stress levels in a reproducible, accessible, and scalable manner. Its versatility and affordability make it a valuable tool for investigating shear stress-related mechanisms in microvascular diseases, particularly PAH, with potential applications in drug discovery and translational research., This research was further supported by the FWO Scientific Research Network (W0014200N). C.B. and M.J.G. are sponsored by the Netherlands Cardiovascular Research Initiative (the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences), PHAEDRA-IMPACT (DCVA), and DOLPHIN-GENESIS (CVON). C.B was sponsored by the European Union’s Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP N° 825575. M.J.G. is supported by regenerative medicine crossing borders (REGMED XB). G.S.D. is supported by the grants Ramón y Cajal RYC2021-030886-I, PID2022-141212OA-I00, and CNS2023-145432 from the Spanish Ministry of Science and Innovation, the BHF-DZHK-DHF, 2022/23 award PROMETHEUS (02-001-2022-0123), and the Foundations Eugenio Rodriguez Pascual (FERP-2023-058) and Mutua Madrileña. F.S. was supported by the Austrian Science Fund (FWF) [doi.org/10.55776/COE7]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interplay between ALK2R206H mutant receptor and autophagy signaling regulates receptor stability and its chondrogenic functions

  • Coculo, Laura
  • Wits, Marius
  • Mariani, Irene
  • Fianco, Giulia
  • Cappato, Serena
  • Bocciardi, Renata
  • Pedemonte, Nicoletta
  • Volpe, Elisabetta
  • Ciolfi, Serena
  • Sessa, Rosario Luigi
  • Rinaldo, Serena
  • Cutruzzolà, Francesca
  • Trisciuoglio, Daniela
  • Goumans, Marie-José
  • Sánchez-Duffhues, Gonzalo
  • Stagni, Venturina
Heterozygous mutations in the Bone morphogenetic protein (BMP) type I receptor ACVR1, encoding activin-like kinase 2 (ALK2), underlie all cases of the rare genetic musculoskeletal disorder Fibrodysplasia Ossificans Progressiva (FOP). The most commonly found mutant ALK2 p.R206H receptor variant exhibits loss of auto inhibition of BMP signaling and can be activated by Activins, while wild-type receptors remain unresponsive. Consequently, the downstream chondrogenic signaling is enhanced, thus driving heterotopic ossification within soft connective tissues. Despite several investigational treatments being evaluated in clinical trials, no cure for FOP exists today. The cellular and molecular mechanisms underlying disease progression are still being deciphered. In this study, we show a close interplay between the mutant ALK2R206H receptor signaling and dysregulation of the autophagic flux triggered by hypoxia. Mechanistically, reduced autophagic flux correlates with increased stability of ALK2R206H, resulting in sustained signaling. Of note, we demonstrated that Rapamycin, under clinical investigation as a treatment for FOP, inhibits chondrogenic differentiation in an autophagy-dependent manner. Consistently, other pharmacological autophagy inducers, like Spermidine, can reduce ALK2R206H driven chondrogenic differentiation in vitro. These results were verified in FOP patient-derived cells. In conclusion, this study shows that aberrant autophagic flux mediates sustained ALK2R206H signaling, introducing a novel druggable target in FOP by reactivating autophagy., We acknowledge the MUR-PON program “IMPARA - Imaging from molecules to preclinical studies” for supporting the implementation of the microscopy infrastructure at IBPM CNR and HypACB infrastructure Sapienza. This research was supported by grants Telethon Seed Grant FOP GSA21A002, Telethon Seed Grant FOP-Renewal GSA23I001, National Recovery and Resilience Plan (NRRP), Mission 4, Component 2, Investment 1.1, Call No. 104 (2.2.2022) by the Italian Ministry of University and Research (MUR), funded by the European Union – NextGenerationEU – PRIN Project N. CUP B53D23015820006 (PRIN202224M22R, to V.S. and L.C.) CUP N. B53D23015930006 (to F.C.), Project N. CUP N. B53D23016330006 (to S.R.), by Short Term Mobility (STM) fellowship (CNR,2022,0039768/2022) for VS, by Ramón y Cajal RYC2021-030866-I, PID2022-141212OA-I00 and CNS2023-145432 from the Spanish Ministry of Science and Innovation for GSD.GSD is also sponsored by the foundations La Marató de TV3 (202038-30), Eugenio Rodriguez Pascual (FERP-2023-058) Foundation “Por dos pulgares de nada” and Mutua Madrileña. MW and MJG are sponsored by the Netherlands Cardiovascular Research Initiative (the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences), PHAEDRA-IMPACT (DCVA), and DOLPHIN-GENESIS (CVON). Work partially supported by CNR (project DBA.AD005.225-NUTRAGE-FOE2021) and PNRR PE8 Age-IT., co-funding from Next Generation EU [DM 1557 11.10.2022], in the context of the NRRP, Investment PE8—Project Age-It (V.S, D.T., and G.F.) and AIRC grant IG2019 no. 23125 (to F.C.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

BMP9 modulates IL-33 signaling to mitigate EndMT in pulmonary arterial hypertension

  • Becher, Clarissa
  • Groeneveld, Esmee J.
  • Quarck, Rozenn
  • Neep, Beau
  • Pan, Xiaoke
  • Szulcek, Robert
  • Tu, Ly
  • Guignabert, Christophe
  • Bogaard, Harm Jan
  • Yu, Paul B.
  • Man, Frances de
  • Sánchez-Duffhues, Gonzalo
  • Goumans, Marie-José
[Background] Pulmonary arterial hypertension (PAH) is a progressive disorder involving disrupted BMP (bone morphogenetic protein) signaling, pulmonary inflammation, and endothelial-to-mesenchymal transition (EndMT). We hypothesized that IL (interleukin)-33 signaling contributes to PAH progression by inducing EndMT and interacting with BMP9, a key modulator of inflammation and vascular remodeling., [Methods] IL-33 expression was assessed in lung tissues from Sugen/hypoxia and control mice, as well as in pulmonary arterial endothelial cells (PAECs) and lung tissues from patients with PAH and healthy donors. EndMT and signaling pathways were analyzed in PAECs and microvascular endothelial cells (MVECs) exposed to IL-33, BMP9, and sST2 (soluble supression of tumorigenicity 2) using quantitative polymerase chain reaction, Western blotting, ELISA, and immunostaining. Plasma BMP9 and sST2 levels were quantified in patients with PAH., [Results] Immunofluorescent analysis revealed elevated IL-33 expression in pulmonary endothelial cells of Sugen/hypoxia mice compared with controls, consistent with findings in PAECs from patients with PAH. BMP9 significantly upregulated sST2 expression in human PAEC and microvascular endothelial cells, inhibited IL-33 target gene expression, and effectively suppressed IL-33-induced EndMT. Notably, BMP9 demonstrated greater efficacy in preventing EndMT compared with rsST2 (recombinant soluble ST2) or ST2L-neutralizing antibodies. Circulating BMP9 and sST2 levels in the plasma of patients with PAH were positively correlated in specific patient groups stratified by sex, age, and New York Heart Association functional class, suggesting a protective role of BMP9 in modulating IL-33-induced EndMT., [Conclusions] BMP9 plays a protective role against IL-33-induced EndMT in PAECs by upregulating sST2 expression and neutralizing IL-33, suggesting that targeting the IL-33 signaling pathway may represent a promising therapeutic strategy to mitigate EndMT in PAH., This work was supported by the FWO Scientific Research Network (grant W0014200N). C. Becher and M.J. Goumans are sponsored by the Netherlands Cardiovascular Research Initiative (the Dutch Heart Foundation, the Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Arts and Sciences), PHAEDRA-IMPACT (Dutch Cardiovascular Alliance, DCVA), and DOLPHIN-GENESIS (CardioVasculair Onderzoek Nederland, CVON). C. Becher is sponsored by the European Joint Program on Rare Diseases and the Company of Biologists. M.J. Goumans is supported by Regenerative Medicine Crossing Borders. G. Sanchez-Duffhues is supported by the grants Ramón y Cajal RYC2021-030866-I, PID2022-141212OA-I00, and CNS2023-145432 from the Spanish Ministry of Science and Innovation, the British Heart Foundation (BHF)-German Centre for Cardiovascular Research (DZHK)-Dutch Heart Foundation (DHF), 2022/23 award PROMETHEUS (grant 02-001-2022-0123), and the Foundation Eugenio Rodriguez Pascual (grant FERP-2023-058). T, Peer reviewed